NCT07486401

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: National Healthcare Group Polyclinics · Other Government
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

Conditions

• Asthma Exacerbations
• Biomarkers / Blood
• Eosinophil Blood Count

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Biomarker-directed treatment for asthma management	Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
OTHER	Usual Care	Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils

Timeline

• Start date: 2025-12-03
• Primary completion: 2028-12-31
• Completion: 2029-12-31
• First posted: 2026-03-20
• Last updated: 2026-03-20

Locations

1 site across 1 country: Singapore